Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Ariad Pharmaceuticals, Inc.    

ARIAD PHARMACEUTICALS, INC.
Mes dernières consult.
Most popular
Report
SummaryNewsCompany 
News SummaryMost relevantAll newsSector newsTweets

Ariad Pharmaceuticals, Inc. : ARIA, XOMA, PRAN and NIHD added to NASDAQ Active Stock Watch List at EPR

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/31/2013 | 03:15pm CET

New York, NY - (ACCESSWIRE) - 10/31/2013 - Equity Profile Report initiates its NASDAQ Active Stock Weekly Watch List adding Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), XOMA Corporation (NASDAQ:XOMA), Prana Biotechnology Limited (NASDAQ:PRAN) and NII Holdings Inc. (NASDAQ:NIHD)

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) an oncology company that focuses on the discovery, development, and commercialization of medicines for cancer patients is currently down (-38.13%) on 26,575,426 shares traded after Ariad suspended sales of cancer pill Iclusig. Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) is currently down (-90.81%) from its recent 52-week high, which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about Ariad Pharmaceuticals Inc. (NASDAQ:ARIA)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=ARIA&SubId=AW

XOMA Corporation (NASDAQ:XOMA) a company that discovers and develops antibody-based therapeutics in the United States, Europe, and the Asia Pacific is currently up (+4.35%) on 712,280 shares traded after XOMA Corporation announced very encouraging results from two Phase 2 clinical studies that are part of the Company's broad gevokizumab proof-of-concept program. XOMA Corporation (NASDAQ:XOMA) is currently up (+95.78%) from its recent 52-week low, which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about XOMA Corporation (NASDAQ:XOMA)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=XOMA&SubId=AW

Prana Biotechnology Limited (NASDAQ:PRAN) a company that researches and develops therapeutic drugs for the treatment of neurological disorders in Australia is currently up (+1.80%) on 563,051 shares traded after Prana's PBT2 Reversed Memory Loss in Normal Aging. Prana Biotechnology Limited (NASDAQ:PRAN) is currently up (+161.31%) from its recent 52-week low, which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about Prana Biotechnology Limited (NASDAQ:PRAN)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=PRAN&SubId=AW

NII Holdings Inc. (NASDAQ:NIHD) a company that through its subsidiaries, provides wireless communication services under the Nextel brand name to businesses and individuals in Mexico, Brazil, Argentina, Peru, and Chile is currently down (-19.58%) on 2,272,972 shares traded after NII Holdings, Inc. Discussed Q3 2013 Results. NII Holdings Inc. (NASDAQ:NIHD) is currently down (-61.3%) from its recent 52-week high, which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about NII Holdings Inc. (NASDAQ:NIHD)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=NIHD&SubId=AW

Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.equityprofilereport.com/

Disclosure: Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.

Contact Info:
Equity Profile Report
[email protected]


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ARIAD PHARMACEUTICALS, INC
02/18 ARIAD PHARMACEUTICALS : Medinol Announces Appointment Of Harvey J. Berger, M.D.,..
02/18 TAKEDA PHARMACEUTICAL : Japans Takeda acquires US cancer drug manufacturer ARIAD..
02/16 ARIAD PHARMACEUTICALS INC : Entry into a Material Definitive Agreement, Completi..
02/16 ARIAD PHARMACEUTICALS : Announces Submission of Marketing Authorization Applicat..
02/06 ARIAD PHARMACEUTICALS INC : Other Events, Financial Statements and Exhibits (for..
02/06 LAWSUIT FOR INVESTORS AGAINST ACQUIS : ARIA) Filed
02/06 ARIAD PHARMACEUTICALS : Announces Submission of Marketing Authorization Applicat..
02/03 ARIAD PHARMACEUTICALS : Enters into Definitive Agreement to Be Acquired by Taked..
02/03 ARIAD PHARMACEUTICALS : Takeda to Acquire ARIAD Pharmaceuticals, Inc.
01/26 TAKEDA PHARMACEUTICAL : Commences Cash Tender Offer for All Outstanding Shares o..
More news
News from SeekingAlpha
04/30 3 THINGS IN BIOTECH YOU SHOULD LEARN : April 30, 2017
04/18 SNIPPET ROUNDUP : Aerie Stumbles On Safety; Stada Is Sold At Last
04/11 First-Quarter Deal Making Shows Glimmers Of Growth
03/31 WHAT TO WATCH IN Q2 : Upcoming Healthcare Regulatory Events
03/07 Roche Looks Ready To Rule Another Cancer Niche
Managers
NameTitle
Christophe M. Bianchi President
Timothy P. Clackson CSO, President-Research & Development
Nicholas Ventresca Chief Information Officer & Senior Vice President
Liza Heapes Associate Director-Corporate Communications
David C. Dalgarno Vice President-Research Technologies
Sector and Competitors
1st jan.Capitalization (M$)
ARIAD PHARMACEUTICALS, INC.0
GILEAD SCIENCES6.94%98 689
REGENERON PHARMACEUTICALS5.33%41 789
VERTEX PHARMACEUTICALS96.55%36 888
GENMAB-11.85%9 967
BLUEBIRD BIO INC199.68%8 385